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Immunotherapy of cancer is receiving much attention for the unquestion-
able success that some modalities have shown in inducing clinical regres-
sions of metastatic disease and improvement in overall survival of several
groups of patients affected not only by classically immune responsive
cancers such as melanoma but also others such as lung cancer. In particular,
the inhibition of immune regulatory and immune suppressive mechanisms
has demonstrated efficacy by directly enhancing the frequency of immune
rejection of cancer or, indirectly, by improving the efficacy of other treat-
ments. However, increased understanding of the biologic requirements of
human cancers that determine the success of immune therapy point to the
conclusion that this modality may be effective only in a subset of patients
bearing tumors that constitutively display an already active immune micro-
environment characterized by lymphoid infiltration and activation of im-
mune effector mechanisms. A majority of tumors instead display a silent
phenotype that is not conducive to immune responsiveness unless new
strategies to re-direct their biology will be devised.
In particular, two phenomena are becoming increasingly more apparent: (1) a
specific functional orientation of cancer infiltrating immune cells is determin-
ing cancer immune responsiveness to treatment and (2) immune suppression
that limits responsiveness coincides with the immune active phenotype as it is
meant to strike a balance within an immunologically active microenviron-
ment. The remainder (and arguably the majority of cancers) is immunologi-
cally silent and, therefore, treatments that aim at relieving immune
suppression such as the checkpoint inhibitors as single treatment modality
will likely not work because there is nothing to suppress to start with. Thus,
the future of immune therapy will have to focus on one side in improving the
efficacy of current modalities that act on cancers prone to respond to immune
manipulation, on the other side to add new modalities that can precondition
the immune environment of immunologically silent tumors.
This issue of Current Opinions offers a review of salient topics that illustrate
the complex biology that underlies the effectiveness of immune therapy.
Success will depend on an accurate understanding of the mode of action of
therapies used and on the weight that several biological factors can play on
immune responsiveness. Such factors can be clustered into three main
categories: those related to the genetic background of the cancer-bearing
host, those related to environmental modulation of the host’s immune system
and finally, factors related to the genetic alterations of individual cancers.
Becht et al. demonstrated that the immune contexture of tumor lesions is
clearly associated with better prognosis in several cancer types. This concept
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of tumor infiltrating immune cells is associated with a
better response to standard therapy (e.g. chemotherapy
and radiotherapy) and longer overall survival. This con-
cept has been demonstrated by various independent
studies from several investigators. Moreover, the immune
contexture is a predictor of the response to immunother-
apy suggesting that the activation of effector immune
responses is part of a continuum spectrum of immune
surveillance. Expanding on these observations,
Bedognetti et al. speculate on the root cause of this cancer
phenotype addressing genetic and environmental deter-
minants of the activated immune phenotype. Among the
various factors, the somatic make up of cancer cells, is
likely to play a dominant role. It is possible that powerful
oncogenic pathways that drive tumor growth may simul-
taneously affect immune responses. In fact, most path-
ways such as the MAP kinase, the b-catenin or the mTor
pathways have dual effects controlling cell growth while
modulating the immune microenvironment through in-
duction of the expression of growth factors, cytokines
and chemokines that affect immune cells function. Lau
et al. point at evidence that targeting the oncogenic
pathway in melanomas (e.g. BRAF) in fact may not only
result in lower proliferation of melanoma cells but also
increase their immunogenicity.  Rational design of such
inhibitors with immunological checkpoint blockers is
warranted.
It is also becoming increasingly accepted that the
mutational load within cancer cells created by the
intrinsic genetic instability of the disease, stochastically
enhances the chance of the expression of altered pro-
tein components that can be seen as ‘neo-antigen’ by
the host immune system and, therefore, are not subject
to natural tolerance mechanisms. Vormehr et al. de-
scribe the technical advances made to identify these
neo-antigen bringing personalized medicine–in the
form of neo-epitope vaccines or TCR-redirected T
cells — very close to the clinic. The observation that
CD4+ T cells also recognize neo-epitopes reignites the
study of their role in tumor control. Similarly, Verdegaal
argues that the success of adoptive cell therapy for
hematological malignancies and solid tumors is based
on CD4+ and CD8+ T cells and neo-epitope specificity.
In an overview of the scientific basis for cell therapy
ways to reduce side effects and immune suppressive
factors requiring attention for therapy improvement are
provided.
The legitimacy of this theory has to face, however, some
basic challenges. Recognition of tumor-specific antigens
requires their processing and presentation by major histo-
compatibility molecules. However, as discussed by
Garrido et al. the expression and function of molecules
necessary for classical antigen processing and presenta-
tion are often reduced if not completely shutdown inwww.sciencedirect.com several tumors. Therefore, better interpretation of this
theory will be possible when both of these parameters
(mutational burden and antigen presenting capability by
cancer and immune cells) will be considered and analyzed
in the same specimens. It should be expected that tumors
should not display an immunogenic phenotype in the
context of major histocompatibility molecule loss in de-
pendent of mutational status.
Tagliamonte et al. extend this discussion to hepatocellular
carcinoma, a highly immune resistant tumor type, which
is caused by a strong intrinsic immune suppressive mi-
croenvironment. Bronte and Munn discuss such immune
suppressive mechanisms in the tumor microenvironment
and how they affect immune responsiveness. A complex
topic indeed that covers the broad spectrum of stromal
myeloid and lymphoid cells limiting anti-cancer activity
by the host’s immune system emphasizing the inducible
and plastic nature of suppressive mechanisms and conse-
quently discussing potential strategies to interfere with
their deleterious effects. Another layer of immune control
and regulation in cancer potentially is caused by the
patient’s microbiota. Perez-Chanona and Trinchieri ar-
gue that a major determinant of immune responsiveness
is the relationship between the intestinal bacteria and the
immune response in the host’s gut, secondarily affecting
the systemic immune status. The gut microbiota plays a
role in educating the host’s immune landscape and as
such will determine cancer responsiveness not only to
immunotherapy but also to standard therapies such as
chemotherapy.
The intricate relationship between immune factors and
chemotherapy responsiveness should not come as a sur-
prise. Although the cytotoxic effect of these drugs under-
lie the primary reason for their use, their multiple
secondary effects on the immune system are now recog-
nized as an important part of their long term effects. Cook
et al. review our current understanding of the immuno-
logical changes associated with chemotherapy and how
chemotherapy can be put in use for other immunothera-
peutic approaches.
Finally, Finn and Beatty suggest a new role for immuno-
therapy as a modality of cancer prevention. After all, the
immune system should have an easier job when trans-
forming cells are still at a premalignant stage or when the
actual tumor burden is minimal and the biology has not
had the time to evolve into a more immune suppressive
and immune evasive phenotype.
Several topics remain to be discussed that were beyond
the purpose of this collection. For instance, the need to
identify useful predictive and prognostic biomarkers that
are highly needed to tailor the right combination of
therapies that are now being selected rather according
to an empirical process. Notably, re-appreciation ofCurrent Opinion in Immunology 2016, 39:viii–x
x Tumour immunologyclassical MHC expression but also the expression of
non-classical MHC molecules, all of which are associated
with immune regulation, will be essential. Next, it will
be important to redefine the role of shared tumor anti-
gens as this topic has been somewhat overshadowed by
the focus on neo-antigens. Also it is becoming increas-
ingly recognized that B cells may play a more important
role in cancer immune rejection than previously appre-
ciated and more work will need to focus on this topic in
the future.Current Opinion in Immunology 2016, 39:viii–x A key question remain about how immunotherapy can
expand to other tumor types with lower immunogenic
potential exploiting novel therapeutic strategies and com-
binations such as the abscopal effect induced by radiation
therapy. And finally, how can novel technologies such as
nanotechnology, integrated approaches and novel imag-
ing techniques can optimize cost/effectiveness of correl-
ative studies for more efficient identification of useful
biomarkers.www.sciencedirect.com
